Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 6/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 8/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.54 |
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.54 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.54 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.53 |
| ▸ | LMNA | P02545 | 5/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.52 |
| ▸ | PPARG | P37231 | 1/20 | 0.51 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1728691 | 0.86 | MAPT (0.64) | HPGDHTTMAPTALDH1A1MEN1 | |
| SCHEMBL27330465 | 0.83 | KDM4E (0.58) | HPGDHTTMAPTALDH1A1MEN1 | |
| SCHEMBL6010140 | 0.83 | PIK3CA (0.57) | HPGDHTTMAPTALDH1A1MEN1 | |
| SCHEMBL3030714 | 0.80 | ALDH1A1 (0.50) | HPGDHTTMAPTALDH1A1MEN1 | |
| SCHEMBL6009501 | 0.80 | ALDH1A1 (0.62) | HPGDHTTMAPTALDH1A1MEN1 | |
| SCHEMBL4030956 | 0.80 | PTPN1 (0.50) | HPGDHTTMAPTALDH1A1MEN1 | |
| SCHEMBL2559322 | 0.80 | POLB (0.60) | HPGDHTTMAPTALDH1A1MEN1 | |
| SCHEMBL1616299 | 0.79 | KDM4E (0.58) | HPGDHTTMAPTALDH1A1MEN1 | |
| SCHEMBL6009509 | 0.76 | SLC9A1 (0.56) | HPGDHTTMAPTALDH1A1MEN1 | |
| SCHEMBL6009560 | 0.76 | SLC9A1 (0.56) | HPGDHTTMAPTALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025096783-A1 | ENHANCERS OF PARTICULATE GUANYLYL CYCLASE RECEPTOR B | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2025-05-08 | — | — | WO | disclosed |
| WO-2024103400-A1 | POLYCYCLIC COMPOUND AS GPR75 ACTIVATOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | 水木未来(北京)科技有限公司 | 2024-05-23 | — | — | WO | disclosed |
| US-7432263-B2 | Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them | PFIZER ITALIA, S.R.L. (IT) | 2008-10-07 | — | — | US | disclosed |
| EP-1427708-B1 | AMINO-PHTHALAZINONE DERIVATIVES AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PFIZER ITALIA SRL (IT) | 2008-09-10 | — | — | EP | disclosed |
| US-20060264493-A1 | Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (IT) | 2006-11-23 | — | — | US | disclosed |
| US-20050020583-A1 | Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them | PFIZER ITALIA S.R.L. (IT) | 2005-01-27 | — | — | US | disclosed |
| EP-1425015-A4 | TETRAHYDROQUINOLINE DERIVATIVES AS ANTITHROMBOTIC AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2004-12-15 | — | — | EP | disclosed |
| US-6825208-B2 | SELECTIVE INHIBITORS OF SERINE PROTEASE ENZYMES, ESPECIALLY FACTOR VIIA; MODULATION OF THE COAGULATION CASCADE. | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-11-30 | — | — | US | disclosed |
| EP-1425015-A2 | TETRAHYDROQUINOLINE DERIVATIVES AS ANTITHROMBOTIC AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-06-09 | — | — | EP | disclosed |
| US-20030225110-A1 | Tetrahydroquinoline derivatives as antithrombotic agents | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-12-04 | — | — | US | disclosed |
| WO-2003015715-A2 | TETRAHYDROQUINOLINE DERIVATIVES AS ANTITHROMBOTIC AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-02-27 | — | — | WO | disclosed |
| WO-2000032598-A9 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY DISEASES UTILIZING INHIBITORS OF TUMOR NECROSIS FACTOR ACTIVITY | STRUCTURAL BIOINFORMATICS INC (US) | 2000-11-30 | — | — | WO | disclosed |
| WO-2000032598-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY DISEASES UTILIZING INHIBITORS OF TUMOR NECROSIS FACTOR ACTIVITY | STRUCTURAL BIOINFORMATICS INC. (US) | 2000-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225110-A1 | Tetrahydroquinoline derivatives as antithrombotic agents | TFPI, TFPI2, SERPINC1 | HPGD 780/4885HTT 1466/4885MAPT 4276/4885 |
| US-20060264493-A1 | Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | MAP3K1, MAP3K19, MAP3K20 | HPGD 3207/4885HTT 1201/4885MAPT 639/4885 |
| US-20050020583-A1 | Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them | MAP3K20, MAP3K1, MAP3K15 | HPGD 3306/4885HTT 1001/4885MAPT 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.